Biocomposites Launches the NanoBone Range in the UK

Biocomposites, an international medical devices company that engineers, manufactures, and markets products for regenerating bone and managing infection in the bone and soft tissue, will begin distributing its NanoBone product range in the UK. 
 
The range consists of NanoBone SBX Putty and NanoBone QD, next-generation synthetic bone grafts that provide reliable early osteogenesis and bone formation. NanoBone is preloaded and ready to use in a wide variety of applications to maximize flexibility and efficiency during procedures.
 
Dr. Walter Gerike, Managing Director of Biocomposites GmbH, said: “NanoBone is a proven technology that has already helped over 100,000 patients throughout the world. The UK is a significant market, and we are very pleased to start selling our innovative range of ready-to-use products there. This development furthers Biocomposites’ position as the go-to provider for surgeons requiring advanced bone regeneration materials.”
 
NanoBone’s patented technology consists of nanostructured hydroxyapatite embedded in a silica gel matrix, which is suspended in a hydrogel/polymer silica carrier. This formulation provides the fullest support for bone regeneration – providing a comparable healing rate to autograft and osteoinductive properties, without the costs and complications of harvesting. 
 
Biocomposites purchased NanoBone last year. Following the acquisition, Biocomposites has successfully integrated and developed the NanoBone range, aiming to serve a greater number of surgeons and patients through its global distribution network.
 
Biocomposites will also attend the British Orthopaedic Association’s Annual Congress 2024, from 17-20 September 2024 at The International Convention Centre in Birmingham.